<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8648206
   </pmid>
   <datecreated>
    <year>
     1996
    </year>
    <month>
     07
    </month>
    <day>
     25
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1996
    </year>
    <month>
     07
    </month>
    <day>
     25
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0022-1899
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       173
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        1996
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of infectious diseases
     </title>
     <isoabbreviation>
      J. Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
    </articletitle>
    <pagination>
     <medlinepgn>
      1347-53
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Human immunodeficiency virus (HIV)-infected persons are less likely than are noninfected persons to respond to vaccination with pneumococcal polysaccharides (PPS). Among those who respond, however, similar IgG levels may be achieved. HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-level responders (IgG &gt; or = 1 microgram/mL for &gt; or = 3 of 5 PPS [high] or for &lt; or = 1 PPS [low]). One and 2 years after immunization, geometric mean IgG levels and the percentages of subjects with IgG levels &gt; or = 1 microgram/mL were similar for HIV-infected and for healthy high-level responders (controls) for all PPS except for serotype 8. Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses. Responsiveness of HIV-infected white patients was significantly associated with the Km(1)- negative allotype. These findings support current general recommended guidelines for administering pneumococcal vaccine to HIV-infected persons. Nonresponders will not benefit from revaccination.
     </abstracttext>
    </abstract>
    <affiliation>
     Medical Service, VA Medical Center, Houston, TX 77030, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Rodriguez-Barradas
      </lastname>
      <forename>
       M C
      </forename>
      <initials>
       MC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Groover
      </lastname>
      <forename>
       J E
      </forename>
      <initials>
       JE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lacke
      </lastname>
      <forename>
       C E
      </forename>
      <initials>
       CE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gump
      </lastname>
      <forename>
       D W
      </forename>
      <initials>
       DW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lahart
      </lastname>
      <forename>
       C J
      </forename>
      <initials>
       CJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pandey
      </lastname>
      <forename>
       J P
      </forename>
      <initials>
       JP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Musher
      </lastname>
      <forename>
       D M
      </forename>
      <initials>
       DM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, Non-P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Infect Dis
    </medlineta>
    <nlmuniqueid>
     0413675
    </nlmuniqueid>
    <issnlinking>
     0022-1899
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antibodies, Bacterial
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antigens, Bacterial
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Bacterial Capsules
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Bacterial Vaccines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunoglobulin Allotypes
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunoglobulin G
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pneumococcal Vaccines
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <citationsubset>
    X
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antibodies, Bacterial
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antigens, Bacterial
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bacterial Capsules
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Bacterial Vaccines
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      HIV Infections
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunization Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunization, Secondary
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoglobulin Allotypes
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoglobulin G
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pneumococcal Infections
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pneumococcal Vaccines
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Streptococcus pneumoniae
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vaccination
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1996
     </year>
     <month>
      6
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8648206
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

